Adagene (ADAG)

Adagene Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ADAG

1 2 3 4 Next >>

Date	Time	Source	Headline	Symbol	Company
07/11/2024	21:00	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:ADAG	Adagene Inc
07/11/2024	21:00	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:ADAG	Adagene Inc
07/11/2024	15:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
07/11/2024	15:01	GlobeNewswire Inc.	Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc	NASDAQ:ADAG	Adagene Inc
09/10/2024	10:00	GlobeNewswire Inc.	Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting	NASDAQ:ADAG	Adagene Inc
24/09/2024	14:26	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:ADAG	Adagene Inc
16/09/2024	13:21	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
16/09/2024	07:01	GlobeNewswire Inc.	Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC	NASDAQ:ADAG	Adagene Inc
29/08/2024	11:00	GlobeNewswire Inc.	Adagene to Participate in Investor Conferences in September	NASDAQ:ADAG	Adagene Inc
25/07/2024	20:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
25/07/2024	20:05	GlobeNewswire Inc.	Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
12/07/2024	11:00	GlobeNewswire Inc.	Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September	NASDAQ:ADAG	Adagene Inc
22/05/2024	20:45	GlobeNewswire Inc.	Adagene to Present at Investor Conferences in June	NASDAQ:ADAG	Adagene Inc
29/03/2024	13:00	GlobeNewswire Inc.	Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
07/03/2024	21:01	GlobeNewswire Inc.	Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board	NASDAQ:ADAG	Adagene Inc
01/03/2024	21:30	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:ADAG	Adagene Inc
27/02/2024	13:00	GlobeNewswire Inc.	Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	NASDAQ:ADAG	Adagene Inc
09/02/2024	11:08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
09/02/2024	11:00	GlobeNewswire Inc.	Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stab	NASDAQ:ADAG	Adagene Inc
16/01/2024	22:01	GlobeNewswire Inc.	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	NASDAQ:ADAG	Adagene Inc
16/01/2024	22:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
04/01/2024	10:00	GlobeNewswire Inc.	Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium	NASDAQ:ADAG	Adagene Inc
03/11/2023	16:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
03/11/2023	16:00	GlobeNewswire Inc.	Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023	NASDAQ:ADAG	Adagene Inc
12/10/2023	12:00	GlobeNewswire Inc.	Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	NASDAQ:ADAG	Adagene Inc
29/09/2023	10:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
07/09/2023	10:00	GlobeNewswire Inc.	Adagene to Present at Investor and Scientific Conferences in September	NASDAQ:ADAG	Adagene Inc
31/08/2023	11:32	GlobeNewswire Inc.	Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
31/08/2023	11:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
07/07/2023	20:34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc